Further dissection of clinical transcriptomic datasets shows no increase in TGFBR2 expression in samples derived from GBM patients upon first (treatment naïve) or second (post-therapy) resection (Supplementary Fig. 2a), however, TGFBR2 transcripts are consistently upregulated in clinical GBM specimens of the mesenchymal subtype (Supplementary Fig. 2b). The gene discussed is TGFBR2; the disease is glioblastoma.